Illumina, Inc. (ILMN) and GENpathway Inc. Announce Partnership to Provide Whole-Genome ChIP-Sequencing Services
4/30/2008 9:24:47 AM
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Genpathway today announced the formation of a partnership to provide researchers whole-genome chromatin immunoprecipitation (ChIP) sequencing services. Samples are first prepared using Genpathway’s FactorPath ChIP assays, and then sequenced by the Genome Analyzer through Illumina’s Sequencing Services. Final data analysis is completed by Genpathway using their proprietary software analysis tools. Combined, the Illumina and Genpathway services provide researchers with access to a complete ChIP-sequencing solution for identifying and quantifying transcription factor binding sites across the entire genome.
comments powered by